neuraminidase

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two upcoming presentations at IDWeek 2024, to be held October 16–19, 2024 in Los Angeles, CA. The presentations will highlight clinical data on the safety, pharmacokinetics, and prophylactic activity of Cidara’s clinical-stage influenza DFC asset, CD388. “We are pleased to share these clinical results at this year’s IDWeek, which underscore the potential for CD388 as an effective and well-tolerated DFC for single-dose, season-long prevention of influenza,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We hope to share the results of our ongoing NAVIGATE Phase 2b clinical trial of CD388 at next year’s meeting.” Oral Presentation Title:CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model Presenter:Taylor Sandison, MD, MPH, Cidara TherapeuticsSession:Inhaling Insight: Advancements in Respiratory Viral InfectionsSession Location:408ADate/Time:Saturday, October 19, 2:21–2:39 PM Pacific Time (PT)Summary:An analysis was conducted to determine prophylactic activity of CD388 against influenza disease in a Phase 2a human challenge study. The study found that a single subcutaneous dose of CD388 administered 5 days prior to influenza challenge was effective in preventing symptomatic disease among those who demonstrated seroconversion following influenza challenge. Poster and Rapid-Fire Presentation: Title:Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic InfluenzaPresenter:Shawn Flanagan, Ph.D., Cidara TherapeuticsSession:Novel AgentsSession Location:Halls JKDate/Time:Friday, October 18, 2024, 12:15–1:30 PM (12:15 - 12:45 for rapid fire presentation) PTSummary:The safety, tolerability, and pharmacokinetics (PK) of CD388 were evaluated in healthy subjects administered either intramuscularly or subcutaneously with varying dosages of the drug. Absorption of CD388 was rapid both intramuscularly and subcutaneously, and elimination was slow, indicating that seasonal influenza prevention could be achieved with one dose per season. There was a lack of anti-drug antibody formation with repeat administration, supporting annual use of CD388, and no safety concerns were noted. About CD388CD388 is an investigational drug-Fc conjugate (DFC) comprised of multiple copies of a potent small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody. DFCs are not vaccines or monoclonal antibodies but are low molecular weight biologics which are designed to function as long-acting small molecule inhibitors. CD388 was designed to provide universal protection against all known strains of seasonal and pandemic influenza with the potential to provide season-long protection with a single subcutaneous or intramuscular administration. Importantly, because CD388 is not a vaccine, its activity is not reliant on an immune response and thereby is expected to be efficacious in individuals regardless of immune status. More information can be found at: https://www.cidara.com/cloudbreak/influenza/. About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced initiation of a Phase 2b trial in September 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. Forward-Looking StatementsThis release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “believe,” “plan,” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to plans and timing for initiating a Phase 2b clinical trial for CD388 and whether the safety and pharmacokinetic data observed in clinical trials to date will be confirmed with larger studies in different patient populations. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, unanticipated impacts of the workforce reduction, difficulties in obtaining potential partners or other obstacles to clinical development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara’s influenza drug-Fc conjugate (DFC) candidate. “We are pleased to have the opportunity to present at this year’s OPTIONS XII conference and share the clinical data on our universally active influenza preventative, CD388,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “These data support the safety of CD388 administered over a range of doses via multiple routes of administration. Moreover, the pharmacokinetic data support the potential use of CD388 in immune compromised as well as immune competent populations to provide season-long protection against influenza A and B.” Oral PresentationTitle: Safety Data from Phase 1 and Phase 2a Studies of CD388, a Drug Fc-conjugate for Seasonal Pan-Influenza ProphylaxisPresenter: Taylor Sandison, MD, MPH, Chief Medical Officer, Cidara Therapeutics Date/Time: Tuesday, October 1, 2024, 15:51–16:04 AEST This presentation summarizes the safety data from three CD388 clinical trials that involved 108 subjects who were followed for approximately 5–14 months. There were no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs). Overall, CD388 administered via subcutaneous or intramuscular injection was safe and well-tolerated in all three clinical trials. These data support further clinical studies with CD388 for single-dose prevention of seasonal influenza. Poster PresentationTitle: Pharmacokinetics and Safety of CD388 Following Subcutaneous Administration in Healthy Japanese ParticipantsPresenter: Taylor Sandison, MD, MPH, Chief Medical Officer, Cidara Therapeutics Date/Time: Sunday, September 29, 18:30-20:30 AEST This presentation summarizes the pharmacokinetics (PK) and safety data of 27 healthy volunteers of Japanese descent dosed subcutaneously with a single dose of CD388 (50, 150, or 450 mg) or placebo. Overall PK parameters showed low-to-moderate variability across all doses and were similar to results from a previous Phase 1 clinical study in Western participants. Safety observations were comparable across the study arms. There were no clinically significant treatment-emergent adverse events (TEAE). These data support further clinical studies with CD388 in the Japanese population for prevention of seasonal influenza. About CD388CD388 is an investigational drug-Fc conjugate (DFC) comprised of multiple copies of a potent small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody. DFCs are not vaccines or monoclonal antibodies but are low molecular weight biologics which are designed to function as long-acting small molecule inhibitors. CD388 was designed to provide universal protection against all known strains of seasonal and pandemic influenza with the potential to provide season-long protection with a single subcutaneous or intramuscular administration. Importantly, because CD388 is not a vaccine, its activity is not reliant on an immune response and thereby is expected to be efficacious in individuals regardless of immune status. More information can be found at: https://www.cidara.com/cloudbreak/influenza/. About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company plans to advance CD388 into a Phase 2b trial in the 2024 Northern Hemisphere influenza season. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which will be developed to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. Forward-Looking StatementsThis release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “believe,” “plan,” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to plans and timing for initiating a Phase 2b clinical trial for CD388 and whether the safety and pharmacokinetic data observed in clinical trials to date will be confirmed with larger studies in different patient populations. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, unanticipated impacts of the workforce reduction, difficulties in obtaining potential partners or other obstacles to clinical development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UKSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first subjects dosed in the Phase 2b NAVIGATE trial to evaluate the efficacy and safety of CD388 for the pre-exposure prophylaxis of influenza during the current flu season. The Phase 2b clinical trial is a randomized, double blind, controlled trial targeting 5,000 healthy unvaccinated adult subjects who are not at risk of complications from influenza. Three CD388 dose groups or placebo will be administered to subjects as a single dose at the beginning of the influenza season. Subjects will then be followed for the remainder of the influenza season to monitor for breakthrough cases. Rates of laboratory and clinically confirmed influenza will be compared between subjects receiving the various single doses of CD388 or placebo. The study will include sites in the US and UK. “Effective new options are needed to prevent influenza, particularly for people who do not respond well to seasonal flu vaccines,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics. “Since CD388 is not a vaccine, its activity does not rely upon an immune response and is thereby expected to work regardless of immune status. In addition, CD388 has demonstrated the potential to prevent infection by both seasonal and pandemic strains of influenza A and B. We are pleased to reach this important milestone, and look forward to monitoring the progress of the NAVIGATE study as this year’s flu season unfolds.” About CD388 CD388 is an investigational drug-Fc conjugate (DFC) comprised of multiple copies of a potent small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody. DFCs are not vaccines or monoclonal antibodies but are low molecular weight biologics which are designed to function as long-acting small molecule inhibitors. CD388 was designed to provide universal protection against all known strains of seasonal and pandemic influenza with the potential to provide season-long protection with a single subcutaneous or intramuscular administration. Importantly, because CD388 is not a vaccine, its activity is not reliant on an immune response and thereby is expected to be efficacious in individuals regardless of immune status. More information can be found at: https://www.cidara.com/cloudbreak/influenza/. About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company plans to advance CD388 into a Phase 2b trial in the 2024 Northern Hemisphere influenza season. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which will be developed to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. Forward-Looking StatementsThis release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “believe,” “plan,” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to plans and timing for the Phase 2b NAVIGATE clinical trial for CD388, including the speed of patient enrollment and the frequency of influenza infections observed. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, unanticipated impacts of the workforce reduction, difficulties in obtaining potential partners or other obstacles to clinical development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com